이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

활성 중등도에서 세대 vernal keratoconjunctivitis에 대한 3% Diquafosol 안과 용액

2026년 11월 5일 업데이트: The University of Hong Kong

활성 중등도 내지 vernal keratoconjunctivitis에 대한 3% Diquafosol 안과 용액의 무작위 대조 시험

The aim of the study is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution in terms of symptoms and signs of VKC, tear film metrics, ocular surface inflammation and quality of life. Potential beneficial effect of Diquafosol treatment on top of current standard use of topical immunosuppressant therapy in VKC would be studied.

Subject at least aged 6 and above with clinical diagnosis of vernal keratoconjunctivitis would be invited to join this study and perform the following assessments:

  1. best corrected visual acuity,
  2. slit lamp biomicroscope examination,
  3. tear meniscus height and non-invasive keratographic tear breakup time(NIKBUT) measurement,
  4. cornea fluorescein staining (CFS) and
  5. Schirmer's I test. Doctor will prescribe eyedrop, 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion or 0.1% Cyclosporin A cationic ophthalmic emulsion at the end of examination. Subjects will be followed up at 4 weeks, 8 weeks, 16 weeks after treatment.

All participants will be required to answer a standardised questionnaire relating to severity of VKC and dry eye disease.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Aim To compare the four-month clinical efficacy of topical treatment with 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion versus 0.1% Cyclosporin A cationic ophthalmic emulsion in reducing symptoms and signs of active moderate-to-severe vernal keratoconjunctivitis (grade of 2 to 4 on the Bonini severity scale) with keratitis (corneal fluorescein staining score of 1-5 on the modified Oxford scale).

Study design A single-centre prospective double-blinded randomized controlled trial

Hypothesis The addition of topical treatment with 3% Diquafosol ophthalmic solution is superior to 0.1% Cyclosporin cationic ophthalmic emulsion alone in improving symptoms and signs of moderate-to-severe VKC with keratitis at four months of use.

Methods This is a single-centre, prospective, 16-week, randomized, double-blinded controlled clinical trial investigating the clinical efficacy and safety of combined topical treatment with 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion and versus topical treatment with 0.1% Cyclosporin A cationic ophthalmic emulsion in patients with moderate-to-severe vernal keratoconjunctivitis and keratitis. The study will also investigate the longitudinal changes in tear cytokines and correlate them with changes in VKC signs and tear film metrics. The study will be performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization, Good Clinical Practice guidelines, and all applicable laws and regulations. Written informed consent will be obtained from each patient before enrolment in the study. A clinical trials certificate will be obtained from the Department of Health, Hong Kong SAR.

Sample size The study will recruit 94 subjects with moderate-to-severe VKC at eye clinics in Hong Kong West cluster (QMH and GH).

Sample size Calculation Sample size calculation is based on the findings from a prospective study comparing the combined use of 3% Diquafosol and 0.1% Cyclosporin versus 0.1% Cyclosporin alone in the treatment of dry eye disease in 279 subjects [36]. It is anticipated that a similar, if not larger, effective size in VKC patients compared to dry eye patients would be seen. In this study the mean change in cornea staining score between baseline and week 12 was significantly higher in Cyclosporin A and Diquafosol combination therapy (2.91 ± 3.93) than in Cyclosporin A monotherapy (0.93± 2.22). The estimated Cohen's d for this study is approximately 0.620. Based on calculations, approximately 41 participants per group to achieve a study power of 80% with a significance level of 0.05 and the estimated effect size of 0.620 is needed. Considering a 10% dropout rate, the adjusted sample size per group would be approximately 47 participants.

Randomization method Randomisation is conducted by computer-generated random number allocation and will be applied to sequentially enrolled participants. The randomisation schedule is pre-determined, prior to commencing participant recruitment, such that the investigator involved in baseline participant assessment will have no involvement in treatment allocation. Block randomization is performed to ensure 1:1 distribution into treatment groups.

Double-blinding To keep the investigators and subjects blind to the study treatment, all investigational drugs are removed from their commercial packaging, wrapped in aluminium foil, double-wrapped in plastic bags, and distributed to participants by an independent clinical research coordinator.

Rescue Therapy During the study period rescue medication (Loteprednolol 0.5% one drop 4x/day for up to 5 days) is permitted in the event of worsening of ocular surface symptoms. A maximum of 2 courses were allowed between study visits. Any use of rescue therapy is documented in the eyedrop diary and serves as one of the outcome measures.

Patient Workflow The patient workflow is aimed at obtaining clear and comprehensive documentation of symptoms and signs baseline and each subsequent visit after initiation of intervention. Furthermore, documentation of adverse events is achieved via assessment of best corrected visual acuity, intraocular pressure measurement, general periorbital area assessment and slit lamp biomicroscope assessment. See Figure 1. Study Workflow

In particular, the sequence of clinical assessments must be done in order of sequence from least invasive to most invasive, as any touching of the ocular surface or manipulation of the eyelids will stimulate tear secretion. Least invasive tests include imaging-based assessments without manipulation or touching of the ocular surface, include best corrected visual acuity, slit lamp biomicroscope assessment, NIKBUT and tear meniscus height. Mildly invasive tests include those that require gentle touching of the ocular surface, such as fluorescein cornea staining. Moderately invasive tests include those with prolonged ocular surface contact, such as the Schirmer's I test for tear collection

연구 유형

중재적

등록 (추정된)

94

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Kendrick Co Shih
  • 전화번호: 39621412
  • 이메일: kcshih@hku.hk

연구 장소

      • Hong Kong, 홍콩
        • 모병
        • HKU Eye Centre
        • 연락하다:
          • Kendrick Co SHIH
          • 전화번호: 94326271
          • 이메일: kcshih@hku.hk

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Subject at least aged 6 and above
  • Clinical diagnosis of vernal keratoconjunctivitis
  • Evidence of active moderate-to-severe disease: At least Grade 2 on the Bonini scale of VKC clinical presentation (moderate-to-severe) [38].
  • Evidence of keratitis: At least Grade 1 on the Modified Oxford scale for cornea fluorescein staining as reported by Bron et al [39].
  • Experienced 1 or more recurrences of VKC during the previous year

Exclusion Criteria:

  • Nasolacrimal duct obstruction
  • Impaired blinking function
  • Active ocular infection or history of ocular herpes, varicella zoster or vaccinia virus infection
  • Any ocular disease that would require topical ocular treatment during the study
  • Use of cyclosporin A or tacrolimus eyedrops, or use of systemic immunosuppressants within 3 months before enrolment
  • Any ocular surgery within 6 months before enrolment

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion

3% Diquafosol eyedrops 6x/day + 0.1% Cyclosporin A twice a day

This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

활성 비교기: 0.1% Cyclosporin A cationic ophthalmic emulsion

0.1% Cyclosporin A eyedrops twice a day + preservative free sodium hyaluronate eyedrops 6x/day

This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Cornea Fluorescein Staining (CFS) score from baseline to 4 weeks, 8 weeks and 16 weeks between study groups
기간: From baseline to 4 months post- treatment between study groups

Higher values mean inferior outcomes. Graded according to the modified Oxford grading scale (range 0, 0.5, 1, 2, 3, 4, 5). A difference in score of at least 2 levels (i.e. 4 to 2) or complete resolution of staining (i.e. 0) are both considered clinically significant endpoints.

From baseline to 4 months post- treatment between study groups

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of patients requiring rescue topical steroid therapy at 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

Number of patients requiring rescue topical steroid therapy divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Percentage of patients with improvement in Cornea Fluorescein Staining (CSF) at 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

Number of patients with improvement in CFS requiring rescue topical steroid therapy divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Change in best corrected visual acuity from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

From logmar(1.0 to -0.1)

From baseline to 4 months post- treatment between study groups
Change in Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) score from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

Range from 0-28, one mark was collected per patient, with higher scores meaning worse

From baseline to 4 months post- treatment between study groups
Change in Quality of Life in Children with Vernal Keratoconjunctivitis (QUICK) score from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

Range from 0-48, one mark was collected per patient, with higher scores meaning worse outcomes

From baseline to 4 months post- treatment between study groups
Change in NIKBUT from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes.

From baseline to 4 months post- treatment between study groups
Change in tear meniscus height from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

In millimetres. Readings serve as objective parameters for tear volume

From baseline to 4 months post- treatment between study groups
Change in tear cytokines from baseline to 4 weeks, 8 weeks and 16 weeks
기간: From baseline to 4 months post- treatment between study groups

Percentage change in tear cytokines analysis done in lab

From baseline to 4 months post- treatment between study groups

기타 결과 측정

결과 측정
측정값 설명
기간
Incidence of ocular adverse events
기간: From baseline to 4 months post- treatment between study groups

Number of patients with ocular adverse events divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
Incidence of non-ocular adverse events
기간: From baseline to 4 months post- treatment between study groups

Number of patients with non-ocular adverse events divided by all patients participated in this study

From baseline to 4 months post- treatment between study groups
• Incremental cost-effectiveness ratio (ICER) in cost per quality-adjusted life year (QALYs) gained.
기간: From baseline to 4 months post- treatment between study groups

It is defined by the difference in cost between two possible interventions, divided by the difference in their effect.

From baseline to 4 months post- treatment between study groups

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Kendrick Co Shih, The University of Hong Kong, Grantham Hospital

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 2월 9일

기본 완료 (추정된)

2028년 6월 30일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2025년 3월 25일

QC 기준을 충족하는 최초 제출

2025년 3월 25일

처음 게시됨 (실제)

2025년 4월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • VKC001

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .